Aura Biosciences (NASDAQ: AURA) — Perfil da empresa, notícias e dados financeiros
Aura Biosciences is a biotech company focused on innovative treatments for ocular melanoma using virus-like drug conjugate technology.
Aura Biosciences
Aura Biosciences (NASDAQ:AURA) is a biotech company dedicated to developing innovative treatments for cancer patients, with a strong focus on ocular melanoma. By leveraging their unique virus-like drug conjugate (VDC) technology, Aura aims to create targeted therapies that can improve clinical outcomes for patients suffering from this rare and life-threatening disease. The company is deeply committed to pushing the boundaries of cancer therapy, working on projects that could potentially revolutionize the way ocular tumors are treated. Aura's primary objective is to bring safe, effective, and breakthrough treatments to market, offering new hope to those battling cancer.
Resumo
Operações
Produtos e/ou serviços de Aura Biosciences
- Development of a virus-like drug conjugate (VDC) platform to target and destroy cancer cells specifically for ocular melanoma.
- AU-011, a lead candidate from the VDC platform for the treatment of primary choroidal melanoma.
- Clinical trials focusing on the safety and efficacy of AU-011 for early-stage choroidal melanoma.
- Partnerships for expanding the application of the VDC platform to other cancer types beyond ocular diseases.
- Research into next-generation VDCs to enhance specificity and efficacy against solid tumors.
- Initiatives to leverage proprietary technology for developing treatments for rare and aggressive cancers.
equipe executiva do Aura Biosciences
- J. Jill HopkinsChief Medical Officer & President of Research and Development
- Natalie C. HollesPresident, CEO & Director
- Amy ElazzouziSenior Vice President of Finance, Treasurer and Secretary
- Susan Abu-AbsiChief Operating Officer
- Alex DasallaHead of Investor Relations & Corporate Communications
- Julie PersonChief People Officer
- Patrick NealonSenior Vice President of Clinical Development Operations
- Anthony DanielsVP & Therapeutic Area of Head Ocular Oncology
- Erica KratzChief Regulatory & Quality Officer
Principais indicadores financeiros
Resultados divulgados pela Aura Biosciences, em USD.
- Cap. de mercado
- 663,7 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.8
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -112,8 mi | -106,2 mi | |
| 0 | -96,1 mi | -86,9 mi | |
| 0 | -85 mi | -76,4 mi | |
| 0 | -60,3 mi | -58,8 mi |